Stelis Biopharma: Mark W. Womack
Stelis Biopharma Limited, a biopharma and vaccines company and the biotech arm of Strides Pharma Science Limited, has appointed Mark W. Womack as its new CEO.
Womack is also the Managing Director (MD) designate and will be inducted to the Board later subject to necessary statutory clearances and processes. As the company's CEO and MD, Mark will provide strong leadership to drive an aggressive growth and profitability strategy for Stelis across business streams that include global Contract Development and Manufacturing Organization (CDMO) services; a biosimilars pipeline; and vaccines division. He will be responsible for the company's overall strategy and provide the necessary direction and leadership to R&D, manufacturing, business development, and commercial operations.
Before joining Stelis, Mark was the Chief Business Officer for CDMO AGC Biologics. Here, he led the organization to nearly a 3x increase in new sales in two years and drove the acquisition of most of the world's top large pharma companies into their portfolio. Before that, he led the global integration of three former CDMOs that were merged to create AGC Biologics.
Mark has served over 25 years as a management consulting industry leader and C-level client advisor: during this time, he served as the Chief Operating Officer for two international management consulting companies.
Before joining the management consulting industry, Womack led a succession of US Navy units, including serving as a combat centre leader on a destroyer class ship.
Womack is a US citizen, and he will be based at the company's corporate headquarter in Bengaluru, India.
Arun Kumar, Founder, Strides Group, said, "Stelis stands on the cusp of a transition to become a globally recognized biopharmaceutical company while targeting significant growth in the coming years. Mark's strong background in commercial leadership, rich management consulting experience, and network within the biotech CDMO space make him exceptionally well suited to drive this transition for Stelis. We are confident that together Mark and his leadership team will take Stelis through the next level of growth, profitability and industry-leading reputation."
